XTL Biopharmaceuticals Overview
XTL Biopharmaceuticals focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company has three product candidates in clinical development. XTLs hCDR1 peptide is a compound that works via a novel mechanism for the treatment of systemic lupus erythematosus (SLE). hCDR1 has completed three clinical trials involving more than 400 patients. Recombinant erythropoietin is a compound being developed by XTL with the potential to help advanced-stage multiple myeloma patients live longer with a better quality of life. The companys SAM-101 is a proprietary combination of antipsychotic drugs and a known medicinal compound for the treatment of psychotic diseases, with a focus on schizophrenia. SAM-101 has completed a phase 2a study in accordance with the Helsinki guidelines at the Shalvata Medical Center.
Cumulative Funding Raised Over Time ($)
$1.5MAug 2024
$25.9MMar 2006
$28.7MMar 2017
$30.0MNov 2004
Latest News
growth-positive
XTL Names Mr. Noam Band as its New Chief Executive Officer
XTL Biopharmaceuticals Ltd. has appointed Noam Band as its new Chief Executive Officer, succeeding Shlomo Shalev, who will continue as Chairman of the Board. Mr. Band brings extensive experience in strategic business development and operational leadership, having previously held executive roles in various technology and digital marketing companies. The company, which holds a 100% share in The Social Proxy Ltd., a web data AI company, is focused on innovation and operational excellence. The appointment is seen as a positive step towards growth and expansion, with a focus on leveraging AI technology for business intelligence applications. The company also holds an IP portfolio for the treatment of Lupus disease.
Management Changes
growth-positive
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
XTL Biopharmaceuticals Ltd. announced the acquisition of THE SOCIAL PROXY Ltd., an AI web data company. The acquisition was completed through a private placement, with XTL acquiring all of the issued and outstanding share capital of Social Proxy. The deal also included the issuance of additional warrants to the shareholders of Social Proxy. The acquisition is part of XTLs strategy to expand its assets portfolio with high potential assets. To support the growth of Social Proxy and the companys financial needs, XTL also completed an investment of US$1,500,000 through a private placement.
AcquisitionInvestment
growth-positive
XTL Entered Definitive Agreement to Acquire The Social Proxy
XTL Biopharmaceuticals Ltd. has announced its acquisition of THE SOCIAL PROXY Ltd., an AI web data company. The acquisition is part of XTLs strategy to expand its assets portfolio with high potential assets. The company will acquire all of the issued and outstanding share capital of Social Proxy in exchange for the issuance of ADSs of the company and a payment of US$430,000 to the shareholders of Social Proxy. In addition, XTL has secured a commitment of an investment amount of US$1,500,000 through a private placement to support the company’s financial needs and complete the transaction.
AcquisitionInvestment
growth-positive
XTL To Aquire The Social Proxy
XTL Biopharmaceuticals Ltd. has announced its plans to acquire THE SOCIAL PROXY Ltd., a web data AI company. The acquisition will be made in exchange for the issuance of ADSs of the Company and a payment of US$430,000 to the shareholders of Social Proxy. As part of the transaction, XTL has secured a commitment of an investment of US$1,500,000 through a private placement. The investment is conditioned upon obtaining shareholders’ approval as Mr. Alexander Rabinovich, a shareholder and a director of the Company, is one of the investors in this Private Placement. The completion of the transaction is subject to various conditions.
AcquisitionInvestment
growth-positive
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel
XTL Biopharmaceuticals Ltd., a clinical stage biopharmaceutical company based in Israel, has confirmed that its operations remain unaffected by the recent terrorist attacks and subsequent declaration of war by the Israeli government against Hamas. The company, which focuses on treatments for systemic lupus erythematosus and Sjögren’s syndrome, continues to operate normally and is exploring collaborations with strategic partners for further clinical trials. Additionally, XTL is looking to expand its portfolio by identifying new assets. The companys headquarters are located near Tel Aviv, away from conflict zones, ensuring business continuity. XTL is publicly traded on the Nasdaq and Tel Aviv Stock Exchange.
PartnersExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $30.04M |
| Last funding | $1.5M |
| Stage | Public |
| Rounds | 6 |
| Investors | 8 |
Team Members
1
Employees: 1-10
Web & Social Links
| Website | xtlbio.com/ |
Locations
HaHaroshet St 5, Ra'anana, Israel
Photos & Videos
1 item(s)
XTL Biopharmaceuticals Business
Business models
B2B, B2B2C
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsTags (5)
oncologyschizophreniapsychiatrybiopharmaceuticalpharma-companiesGeographic Markets
IsraelXTL Biopharmaceuticals Financials
$30.04M
Total funding
Undisclosed
Capital raised
$1.5M
Last funding
Public
Funding stage
6
Total rounds
8
Investors
Cumulative Funding Raised Over Time ($)
$1.5MAug 2024
$25.9MMar 2006
$28.7MMar 2017
$30.0MNov 2004
Private Equity Funding
PIPE
Aug 2024
$1.5M
Undisclosed Investor(s)
PIPE
Mar 2017
$2.8M
Undisclosed Investor(s)
PIPE
Mar 2006
$24.4M
Undisclosed Investor(s)
Seed
Nov 2004
$1.34M
XT Group, Inventech Industrial Ventures, The Challenge Fund, Etgar, Israel HealthCare Ventures, Concord Ventures, Biomedical Investments, Medica Venture Partners
Public Offering / Exit
POEvent
Sep 2000
Undisclosed
POEvent
Sep 2000
Undisclosed
Mergers & Acquisitions
MNAEvent
Aug 2024
Undisclosed
XTL Biopharmaceuticals Lifecycle
Cumulative Funding Raised Over Time
$1.5MAug 2024
$25.9MMar 2006
$28.7MMar 2017
$30.0MNov 2004
All Events
PIPE
Aug 2024
$1.5M
Undisclosed Investor(s)
PIPE
Mar 2017
$2.8M
Undisclosed Investor(s)
PIPE
Mar 2006
$24.4M
Undisclosed Investor(s)
Seed
Nov 2004
$1.34M
XT Group, Inventech Industrial Ventures, The Challenge Fund, Etgar, Israel HealthCare Ventures, Concord Ventures, Biomedical Investments, Medica Venture Partners
POEvent
Sep 2000
Undisclosed
POEvent
Sep 2000
Undisclosed
MNAEvent
Aug 2024
Undisclosed
XTL Biopharmaceuticals News
13 articles
growth-positive
XTL Names Mr. Noam Band as its New Chief Executive Officer
XTL Biopharmaceuticals Ltd. has appointed Noam Band as its new Chief Executive Officer, succeeding Shlomo Shalev, who will continue as Chairman of the Board. Mr. Band brings extensive experience in strategic business development and operational leadership, having previously held executive roles in various technology and digital marketing companies. The company, which holds a 100% share in The Social Proxy Ltd., a web data AI company, is focused on innovation and operational excellence. The appointment is seen as a positive step towards growth and expansion, with a focus on leveraging AI technology for business intelligence applications. The company also holds an IP portfolio for the treatment of Lupus disease.
Management Changes
growth-positive
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
XTL Biopharmaceuticals Ltd. announced the acquisition of THE SOCIAL PROXY Ltd., an AI web data company. The acquisition was completed through a private placement, with XTL acquiring all of the issued and outstanding share capital of Social Proxy. The deal also included the issuance of additional warrants to the shareholders of Social Proxy. The acquisition is part of XTLs strategy to expand its assets portfolio with high potential assets. To support the growth of Social Proxy and the companys financial needs, XTL also completed an investment of US$1,500,000 through a private placement.
AcquisitionInvestment
growth-positive
XTL Entered Definitive Agreement to Acquire The Social Proxy
XTL Biopharmaceuticals Ltd. has announced its acquisition of THE SOCIAL PROXY Ltd., an AI web data company. The acquisition is part of XTLs strategy to expand its assets portfolio with high potential assets. The company will acquire all of the issued and outstanding share capital of Social Proxy in exchange for the issuance of ADSs of the company and a payment of US$430,000 to the shareholders of Social Proxy. In addition, XTL has secured a commitment of an investment amount of US$1,500,000 through a private placement to support the company’s financial needs and complete the transaction.
AcquisitionInvestment
growth-positive
XTL To Aquire The Social Proxy
XTL Biopharmaceuticals Ltd. has announced its plans to acquire THE SOCIAL PROXY Ltd., a web data AI company. The acquisition will be made in exchange for the issuance of ADSs of the Company and a payment of US$430,000 to the shareholders of Social Proxy. As part of the transaction, XTL has secured a commitment of an investment of US$1,500,000 through a private placement. The investment is conditioned upon obtaining shareholders’ approval as Mr. Alexander Rabinovich, a shareholder and a director of the Company, is one of the investors in this Private Placement. The completion of the transaction is subject to various conditions.
AcquisitionInvestment
growth-positive
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel
XTL Biopharmaceuticals Ltd., a clinical stage biopharmaceutical company based in Israel, has confirmed that its operations remain unaffected by the recent terrorist attacks and subsequent declaration of war by the Israeli government against Hamas. The company, which focuses on treatments for systemic lupus erythematosus and Sjögren’s syndrome, continues to operate normally and is exploring collaborations with strategic partners for further clinical trials. Additionally, XTL is looking to expand its portfolio by identifying new assets. The companys headquarters are located near Tel Aviv, away from conflict zones, ensuring business continuity. XTL is publicly traded on the Nasdaq and Tel Aviv Stock Exchange.
PartnersExpand
growth-negative
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
XTL Biopharmaceuticals Ltd. has received a notification from the Nasdaq Stock Market LLC on October 18, 2023, stating that it is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq. The companys American Depositary Shares (ADSs) must close at $1.00 per ADS for a minimum of ten consecutive business days during the compliance period ending April 15, 2024, to regain compliance. If the company fails to regain compliance during this period, it may be eligible for additional time or face delisting.
Public Trading
growth-positive
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel
XTL Biopharmaceuticals Ltd., a clinical stage biopharmaceutical company, has confirmed that its operations in Israel have not been adversely impacted by the recent terrorist attack and subsequent declaration of war by the Israeli government. The companys headquarters are located in the center of the country, away from any borders. The company continues to monitor its ongoing activities and make necessary adjustments to ensure smooth continuity of its business. The company is also looking to expand and identify additional assets to add to its portfolio.
CustomersPartners
growth-negative
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company, has received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement for continued listing. The company has until April 15, 2024, to regain compliance by ensuring its American Depositary Shares (ADSs) close at $1.00 or more for at least ten consecutive business days. Failure to comply may result in delisting, although XTL may qualify for an additional compliance period if certain conditions are met. XTL is exploring strategic partnerships for clinical trials and aims to expand its asset portfolio. Despite the compliance challenge, XTLs shares continue to trade on the Nasdaq Capital Market.
growth-positive
XTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing Investors
XTL Biopharmaceuticals has entered into definitive agreements with existing investors to receive proceeds of $2.8 million in a private placement offering. The company will issue 1,400,000 American Depository Shares (ADSs) at a purchase price of $2.00 per ADS. Each ADS purchased by investors will come with an unregistered warrant to purchase one ADS. The offering is expected to close on or about March 13, 2017. The warrants have a term of five and a half years with an exercise price of $2.30 per ADS. XTL Biopharmaceuticals is a clinical-stage biotech company focused on developing pharmaceutical products for the treatment of autoimmune diseases.
Investment
growth-positive
XTL Biopharmaceuticals to Present at Rodman & Renshaw Conference on September 12, 2016
XTL Biopharmaceuticals Ltd. announced that its Chief Financial Officer will present at an investment conference to provide updates on the companys lead compound for the treatment of lupus. The presentation will include information on hCDR1, a novel compound with clinical data on over 400 patients. XTL is a clinical-stage biotech company focused on developing pharmaceutical products for autoimmune diseases, including lupus. The companys lead drug candidate, hCDR1, has shown efficacy in clinical trials and has been well-tolerated by patients. XTL is traded on the Nasdaq Capital Market and the Tel Aviv Stock Exchange.
Investment
growth-positive
XTL acquires 31% stake in Proteologics from Teva
Proteologics share price has risen after XTL Biopharmaceuticals acquired a 31.3% stake in the company from Teva Pharmaceutical Industries at a 20% premium on the opening price. Before the acquisition, Teva was the controlling shareholder in Proteologics. The acquisition may have been influenced by Proteologics chairmans proposal for a merger with Biocancell Therapeutics. Proteologics is a drug development company focused on discovering inhibitors for specific E3 ubiquitin ligases.
Acquisition
growth-positive
XTL Biopharmaceuticals to Acquire NiCure
XTL Biopharmaceuticals, Ltd. has announced its plan to acquire the technology NiCure from Mor Research Applications. The technology is a novel treatment for cartilage-related diseases and can also be used to treat skin wrinkles. The acquisition is subject to due diligence and regulatory approval. XTL Biopharmaceuticals aims to address the unmet clinical need for a large population. The company is focused on developing a drug for the treatment of multiple myeloma and Hepatitis C. XTL Biopharmaceuticals is a public company traded on the Tel Aviv Stock Exchange.
Acquisition
growth-positive
XTL Bio buys schizophrenia drug developer MinoGuard
XTL Biopharmaceuticals has entered into a term sheet to acquire MinoGuard, a company that develops drugs for mental health diseases. XTL will have an exclusive license to use MinoGuards technology in return for royalties and milestone payments. The acquisition aligns with XTLs strategy to focus on late-stage clinical development drugs and treatments with a known safety profile. MinoGuards lead compound, SAM-101, has shown positive results in a phase IIa clinical trial for the treatment of schizophrenia. Schizophrenia affects a significant portion of the adult population in the US, and the schizophrenia treatment industry was worth $5.6 billion in 2009. XTLs share price rose 2% on the TASE following the announcement.
Acquisition
XTL Biopharmaceuticals Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 3 |
| Team members | 1 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 7 classification IDs that could be used for matching.
XTL Biopharmaceuticals Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 92/100 |
| Missing | markets, not claimed |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 520039470 |
| Crunchbase | xtl-biopharmaceuticals-ltd |
| Phone | +97299557080 |
| Creator | Sharon Shapira |
| Creator email | shapira.sharon2@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-05-24T00:00:00.000Z |
| Created | 2015-05-03T00:00:00.000Z |
| Status detail | Public on NASDAQ on Sep, 2000;Public on TASE on Sep, 2000; |